200
Participants
Start Date
April 1, 2024
Primary Completion Date
April 17, 2025
Study Completion Date
January 31, 2026
phentolamine ophthalmic solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist
Once daily dosing
Placebo
Once daily dosing
United States Smithtown, Smithtown
United States Lynchburg, Lynchburg
United States, North Carolina, Garner
United States, Mt Pleasant, SC, Mt. Pleasant
United States, Jacksonville, FL, Jacksonville
United States Jacksonville, Jacksonville
United States, Tampa
United States Smyrna, Smyrna
United States Chattanooga, Chattanooga
United States Louisville, Louisville
United States Fraser, Fraser
United States Fargo, Fargo
United States Overland Park, Overland Park
United States Draper, Draper
United States Phoenix, Phoenix
United States Scottsdale, Scottsdale
United States Torrance, Torrance
United States, Glendale, CA, Glendale
United States Rowland Heights, Rowland Heights
United States, California, Newport Beach
United States, LaJolla, CA, La Jolla
United States, Bakersfield
United States, Rhode Island, Warwick
Lead Sponsor
Viatris Inc.
INDUSTRY
Ocuphire Pharma, Inc.
INDUSTRY